- Home
- ASYS vs MAIA Comparison
ASYS vs MAIA Comparison
Compare ASYS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASYS | MAIA |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ASYS | MAIA |
|---|---|---|
| Price | $10.94 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 143.3K | ★ 873.7K |
| Earning Date | 12-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $0.87 |
| 52 Week High | $11.55 | $2.74 |
Technical Indicators
Market Signals| Indicator | ASYS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 79.96 | 56.22 |
| Support Level | $8.50 | $1.07 |
| Resistance Level | $9.04 | $1.25 |
| Average True Range (ATR) | 0.69 | 0.16 |
| MACD | 0.33 | 0.06 |
| Stochastic Oscillator | 87.47 | 54.41 |
Price Performance
Historical ComparisonAbout ASYS Amtech Systems Inc.
Amtech Systems Inc is a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips, electronic assemblies, and light-emitting diodes (LEDs). the company has two segments; based on the industries served: Thermal Processing Solutions (formerly called Semiconductor) and Semiconductor Fabrication Solutions (formerly called Material and Substrate). Maximum revenue is generated from Thermal Processing Solutions. Maximum revenue is from Asia Region.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.